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Abstract
The Block 2 region of the merozoite surface protein-1 (MSP-1) of Plasmodium falciparum has been identified as a target of
protective immunity by a combination of seroepidemiology and parasite population genetics. Immunogenicity studies in
small animals and Aotus monkeys were used to determine the efficacy of recombinant antigens derived from this region of
MSP-1 as a potential vaccine antigen. Aotus lemurinus griseimembra monkeys were immunized three times with a
recombinant antigen derived from the Block 2 region of MSP-1 of the monkey-adapted challenge strain, FVO of Plasmodium
falciparum, using an adjuvant suitable for use in humans. Immunofluorescent antibody assays (IFA) against erythrocytes
infected with P. falciparum using sera from the immunized monkeys showed that the MSP-1 Block 2 antigen induced
significant antibody responses to whole malaria parasites. MSP-1 Block 2 antigen-specific enzyme-linked immunosorbent
assays (ELISA) showed no significant differences in antibody titers between immunized animals. Immunized animals were
challenged with the virulent P. falciparum FVO isolate and monitored for 21 days. Two out of four immunized animals were
able to control their parasitaemia during the follow-up period, whereas two out of two controls developed fulminating
parasitemia. Parasite-specific serum antibody titers measured by IFA were four-fold higher in protected animals than in
unprotected animals. In addition, peptide-based epitope mapping of serum antibodies from immunized Aotus showed
distinct differences in epitope specificities between protected and unprotected animals.
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Introduction
The only malaria vaccine to reach Phase 3 clinical trials (RTS,S)
was recently shown to have ,50% protective efficacy against
clinical malaria episodes in 5–17 month old children [1], although
protective efficacy waned rapidly and was lost within 3 years [2].
Any fully successful malaria vaccine will require multiple antigenic
components derived from multiple parasite lifecycle stages,
including antigens from the blood stage, which is often lethal in
unprotected, untreated individuals. The erythrocyte invasive stage
of Plasmodium falciparum, known as the merozoite, is an important
target of immune responses which control parasite numbers and
hence disease severity [3,4]. The most abundant protein on the
surface of the merozoite is the ,190 kDa merozoite surface
protein 1 (MSP-1). This protein is proteolytically cleaved into a
number of fragments during merozoite development and invasion,
and antibodies specific for the C-terminal region of MSP-1 have
been shown to inhibit this processing [5]. These MSP-1 fragments
(p83, p31, p38 and p42) remain as a non-covalent complex on the
surface of the merozoite [6] until the p42 component is further
cleaved at or just before merozoite invasion [7]. MSP-1 has been
the focus of much of the effort to produce an effective vaccine
against malaria, and several regions of this major merozoite
antigen have been included in vaccine formulations used in both
monkeys and humans [8–12]. However, little protective efficacy
has been elicited in non-human primates without the use of very
powerful adjuvants such as Freund’s complete adjuvant, which is
unsuitable for use in humans and can also have adverse side-effects
in the Aotus model [13–15]. Most vaccine studies on MSP-1 have
focused on the conserved C-terminal region of MSP-1, either in
the form of MSP-142 or MSP-119 [8,16]. However, there is
evidence that other regions of MSP-1 can elicit functionally
protective immune responses. In primate models of malaria,
regions of MSP-1 from the N-terminal p83 fragment elicit
protective effects in vivo [17]. Monoclonal and polyclonal
antibodies specific for N-terminal MSP-1 domains have been
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shown to inhibit parasite growth in vitro [18,19]. The Block 2
region of MSP-1 is a small region of hydrophilic, polar amino
acids near the N-terminus of MSP-1, which is highly variable
between parasite isolates [20]. Sequence polymorphism in Block 2
is extensive, but all Block 2 sequences can be assigned to three
major Block 2 serotypes (K1-like, MAD20-like and RO33-like)
named after prototypical parasite strains in which these sequences
were first identified [20–22]. The K1 and MAD20 Block 2 types
contain multiple serine-containing tripeptide repeats, with the
general motif ‘SXX’ [20]. The serine residue in the K1 type of
Block 2 always uses codon AGT, whereas the codon for S in
MAD20 repeats is TCA, presumably to prevent or reduce
recombination between these two sequence types [22]. The
RO33 Block 2 type contains similar hydrophilic amino acid
residues to the other Block 2 types, but is relatively conserved and
non-repetitive [20,22].
We have produced recombinant antigens representing the
highly polymorphic and intrinsically unstructured Block 2 region
of Plasmodium falciparum MSP-1. These proteins are antigenically
similar to the native parasite protein and are immunogenic in
mice, eliciting antibodies which recognize serotype-specific
epitopes within the Block 2 region of the parasite MSP-1 [21].
Human sera from malaria-exposed individuals contain IgG
antibodies that recognize very specifically one or another of the
three Block 2 serotypes, and correlate with PCR typing of parasites
present at the time of infection [23]. Thus, different MSP-1 Block
2 serotypes are immunogenic and antigenically distinguishable
when presented during natural infections in humans. In the
absence of re-infection, antibody responses to MSP-1 Block 2
decline within a few months of drug treatment and parasite
clearance, indicating that naturally induced human antibody
responses to Block 2 are short-lived [23]. Human antibody
responses to MSP-1 Block 2 are predominantly of the IgG3
subclass [24–26], which may explain the short duration of
antibody responses to this region, and at least partially explain
the requirement for continuous stimulation by malaria infection to
maintain clinical immunity to disease in naturally exposed
populations [27,28]. Importantly, and in support of this immuni-
zation and challenge trial, we have shown that serum IgG
antibodies against the two most frequent allelic types of Block 2 of
MSP-1 were strongly associated with protection from P. falciparum
malaria in Gambian children [29,30] and in a cohort of children
from Ghana over a longer follow-up period [25]. Antibodies to
MSP-1 Block 2 are also significantly associated with successful
anti-malarial treatment outcomes in children with uncomplicated
malaria [31]. The mechanism of action of the antibodies to this
polymorphic merozoite antigen have yet to be determined, but
probably do not involve invasion-inhibitory effects [32] and may
rely on more indirect Fc receptor mediated effects involving innate
immune cells [33].
The mechanism(s) of protective immunity to P. falciparum in
humans are still not fully understood, but may rely at least partly
on the acquisition of a network of antibodies to blood stage
parasite antigens [3,4]. Several in vitro assays, such as parasite
growth inhibition assays (GIA) and antibody dependent cellular
inhibition (ADCI) have been developed to test the functional
activity of antibodies to parasite antigens, including MSP-1, but
none of these assays have yet shown any correlation with clinical
efficacy. Although not perfect, non-human primate malaria
models for P. falciparum, in species such as Aotus monkeys, provide
an alternative method of in vivo assessment of candidate malaria
vaccine efficacy [34–36], especially where there is no orthologue in
any rodent malaria parasite protein, as is the case for MSP-1 Block
2. In this study we show that recombinant Block 2 is immunogenic
in mice with a variety of adjuvants suitable for human
immunizations. On the basis of these antigen/adjuvant formula-
tion tests, we have tested and validated a recombinant MSP-1
Block 2 vaccine antigen in Aotus monkeys by an immunization and
virulent parasite challenge trial, using an adjuvant previously used
in several human Phase II trials [37].
Results
Recombinant antigen production
Since the malaria parasite challenge strain used at BPRC is
FVO, recombinant antigens based on the exact MSP-1 Block 2
sequence of the FVO strain were used to produce a homologous
immunizing antigen. Genomic DNA from Aotus blood containing
FVO parasites was used as a template to PCR amplify the Block 2
sequence from the FVO msp-1 gene. This DNA fragment was
cloned into plasmid pGEX-2T as previously described [21,23].
DNA sequencing confirmed that the challenge strain used at
BPRC was identical at the Block 2 locus to the published FVO
msp-1 sequence [38], and to the Block 2 sequence of the Wellcome
isolate [39].
Immunizing antigens were prepared from E. coli strains
harboring the GST-FVO Block 2 plasmid as described in
Materials and Methods. Briefly, the FVO Block 2 antigen was
purified in two forms; as a recombinant protein fused to the C-
terminus of S. japonicum glutathione S- transferase [40] (named
GST-FVO) and as a non-tagged FVO Block 2 protein, produced
by thrombin cleavage from GST-FVO (named FVO). Details of
purification of the two immunogens are given in Materials and
Methods.
Immunogenicity testing of GST-FVO Block 2 and FVO
Block 2 recombinant antigens formulated in human-
compatible adjuvants
ELISA. CBA/Ca or MF1 mice were immunized with either
GST-FVO Block 2 or FVO Block 2 recombinant antigens alone,
in five different adjuvants suitable for use in humans, namely Alum
(Alhydrogel or AdjuPhos), Montanides ISA-51 and ISA-720 and
non-ionic surfactant vesicles (NISV). FVO Block 2 specific
antibodies were detected by ELISA in the sera of the majority of
GST-FVO Block 2 immunized animals 14 days after the third
dose, with median titers in each group ranging from 254
(AdjuPhos, MF1 mice) to 14,498 (NISV, MF1 mice) (Figure 1,
Panel A, left). Montanides ISA-51 and ISA-720 gave the most
consistent antibody titers, with all animals producing significant
titers of antibodies above 275, whereas both Alum adjuvant groups
had some non-responding animals (Figure 1, Panel A, left).
Antibody titers were not significantly lower in the NISV group, but
a trend towards a lower median titer was observed.
A larger proportion of non-responding animals were detected in
the mice immunized with FVO Block 2 alone (12/50) compared to
the four non-responding animals in the GST-FVO immunized
groups. Notably, eight of ten animals immunized with FVO Block
2 alone formulated with NISV had no detectable antibodies to
FVO Block 2 by ELISA. Four non-responders were observed in
the Alum-formulated groups, whereas no mice failed to respond to
FVO Block 2 formulated in either Montanide adjuvant. The FVO
Block 2/NISV group had significantly lower median antibody
titers than several other adjuvant formulations of FVO Block 2
(Alhydrogel, ISA-51 and ISA-720, p,0.05, Kruskal-Wallis test).
IFAT. Serum samples from mice immunized with MSP-1
Block 2 were analyzed by IFA for parasite reactivity with the
Wellcome isolate of P. falciparum by methods previously described
MSP-1 Block 2 Vaccine Protects Aotus Monkeys
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[21,41]. The Wellcome strain was chosen for IFA as it has an
identical MSP-1 Block 2 sequence to the FVO isolate.
Mice immunized with GST-FVO Block 2 produced parasite-
specific antibodies in combination with all adjuvants tested
(Figure 1B, left). All but one animal immunized with GST-FVO
Block 2 with both Montanides ISA51 and ISA720 (9/10 mice) had
detectable IFA titers to Wellcome parasites. Median (range) titers
for the groups were 800 (200–1600) for ISA51/MF1 mice, 400
(100–800) for ISA51/CBA mice, 800 (0–1600) for ISA720/MF1
mice and 400 (200–1600) for ISA720/CBA mice. All four Alum
adjuvant groups had lower IFA titers, (median titers 50–200,
ranges 0–1600) with sera from 5/20 mice showing no detectable
reactivity with parasites. The difference in IFA titers between the
Montanide and Alum GST-FVO Block 2 immunized groups was
not significantly different (p.0.05, Kruskal-Wallis test), but the
higher frequency of non-responders in the Alum groups was
notable. GST-FVO Block 2 formulated in NISV elicited IFA titers
comparable with the Alum adjuvant groups.
By contrast, mice immunized with FVO Block 2 alone
formulated with any of the five adjuvants had low or no
parasite-specific antibodies as measured by IFA (Figure 1B, right).
Only 9/50 animals had detectable anti-parasite antibodies, with
IFA titers ranging from 50 to 200. All other animals had no
reactivity with parasites at a 1:50 dilution of serum. No adjuvant
group had more than three responding animals, and median titers
were 50 or less in all groups (Figure 1B, right). This contrasted
with the FVO Block 2 specific ELISA titers seen in the same sera,
which although generally lower than those observed in the GST-
FVO immunized groups, did not show such a large discrepancy in
antigen-specific titers.
Immunogenicity of GST-FVO Block 2 in Aotus lemurinus
griseimembra
Based on the results of these antigen/adjuvant formulation and
immunization studies in mice, Aotus lemurinus griseimembra monkeys
were immunized with purified GST-FVO Block 2 antigen
formulated with Montanide ISA51 as adjuvant (see Table 1 and
Materials and Methods for details of protocol and animals). Four
animals were immunized three times with GST-FVO Block 2, and
three animals were to receive an identical schedule with
administration of Montanide ISA51 adjuvant alone (Table 2).
One control monkey (A55) died several days after the second
immunization date. Necropsy on the animal showed that death
was caused by a ruptured heart blood vessel, cause unknown, but
not related to experimental procedures. This animal was replaced
with a naı¨ve, non-injected animal (A0001) for the parasite
challenge stage of the study.
All four GST-FVO Block 2 immunized animals responded to
each immunization by the production of antigen-specific IgG
(Figure 2A). ELISA titers in the four animals reached a median
level of 38,763 (range 8027 to 127,910) at day 28 after primary
immunization, increasing to 207,917 (range 96,769 to 325,618) by
Figure 1. Immunogenicity and adjuvant testing of MSP-1 Block 2 proteins from the FVO isolate. Effect of adjuvants on antibody
responses against MSP-1 Block 2. Groups of five outbred (MF1, circles) or inbred (CBA, inverted triangles) mice were immunized s.c. three times at 4
week intervals with FVO MSP-1 Block 2 formulated with the adjuvants as indicated on the X axis. AH, Alhydrogel; AP, AdjuPhos; ISA51, Montanide
ISA51; ISA720, Montanide ISA720; NISV, Non-ionic surfactant vesicles. Two weeks after the last immunization, serum samples were tested by ELISA for
antibody responses against thrombin-cleaved and purified FVO MSP-1 Block 2 (Panel A) and by IFA reactivity with P. falciparum parasites of the
Wellcome isolate, which has the same Block 2 sequence as FVO (Panel B). ELISA and IFA titers were calculated as outlined in Materials and Methods.
Data is shown on a log10 scale as dotplots of serum reactivity for individual animals with the median level of Ab reactivity for each group indicated by
a horizontal line.
doi:10.1371/journal.pone.0083704.g001
Table 1. Details of Aotus lemurinus griseimembra used for
immunization and challenge.
Group Number Sex Age (years) Weight (kg)
Experimental A9801 M 4 0.98
A9802 M 4 0.92
A53 F 7 0.87
A66 M 6 1.02
Control A9804 M 4 0.73
A551 (A0001") M(F") 7(2") 0.93 (0.90")
A9902* F 3 0.98
Donor A31 M 11 0.89
1died of non-immunization causes before challenge.
"naı¨ve (non-injected) animal substitute.
*Removed from experiment after challenge.
doi:10.1371/journal.pone.0083704.t001
MSP-1 Block 2 Vaccine Protects Aotus Monkeys
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day 69 after secondary immunization and 263,692 (range 150,242
to 404,134) by day 97, the day of parasite challenge and 28 days
after the 3rd and final immunization (Figure 2A). There was no
significant difference in FVO Block 2-specific ELISA titers
between immunized animals at any time point (one-way ANOVA,
p = 0.1677).
The same serum samples were tested by IFA against fixed
Wellcome isolate parasites, which have the same MSP-1 Block 2
sequence as FVO. All four GST-FVO Block 2 immunized animals
responded to each immunization by the production of parasite-
specific IgG (Figure 2B). IFA titers in the four animals reached a
median level of 250 (range 100 to 400) at day 28 after primary
immunization, 1200 (range 800 to 6,400) by day 69 after
secondary immunization and 8000 (range 3,200 to 12,800) by
day 97, the day of parasite challenge (Figure 2B). There was a
significant difference in parasite-specific titers between immunized
animals at the day 97 time point (one-way ANOVA, p = 0.0312).
Day 97 sera from two of the four immunized animals (A53 and
A66) had endpoint titers of 12,800; the two other immunized
animals (A9801 and A9802) had day 97 titers of 3,200 by IFA
(Figure 2B). Control animals had no detectable parasite-specific
antibody at any time point. Thus, Ag-specific serum IgG ELISA
titers in each immunized animal did not correspond to the
parasite-specific IFA titer observed in the same samples (Figures 2A
and B).
Course of parasitaemia and outcomes of infection with
FVO parasites
The protective efficacy of antibodies induced by GST-FVO
immunization, compared with administration of adjuvant alone or
in naı¨ve controls was assessed in Aotus lemurinus griseimembra
monkeys. Animals were infected with 105 FVO ring stage parasites
from a donor monkey (A31). One control monkey (A9902) died for
unknown reasons shortly after parasite challenge. All other
animals became patent for parasites (i.e. positive blood film) on
day 8, apart from A53, which became patent on day 9 (Figure 3).
Two of the four GST-FVO Block 2 immunized animals were not
protected, and were treated with mefloquine on days 11 (A9801)
and 12 (A9802) for parasitemias above or approaching 5%. The
two remaining negative control animals were also treated with
mefloquine on days 12 (A9804, adjuvant control) and day 13
(A0001, naı¨ve control) for the same reason. The two remaining
immunized animals (A53 and A66) were defined in this study as
protected from severe infection, i.e. were able to control
parasitaemia below 2.2% throughout the 21-day follow-up period
(Figure 3). One animal (A66) controlled parasite levels below 0.8%
throughout this time, whereas A53 reached a peak parasitaemia of
2.14% on day 16, then maintaining parasite levels at ,1% until
the end of the trial. These two animals were then treated with
mefloquine on day 21 as agreed in the trial protocol. No animal
became anemic during this trial.
Fine-scale epitope mapping of antibody responses to
GST-FVO Block 2 in immunized Aotus
A panel of 38 N-terminal biotinylated 12-mer peptides,
representative of all major linear epitopes in the homologous
Block 2 serotype of MSP-1 were used to fine-scale map antibody
responses in all immunized animals. This peptide panel included
Table 2. Schedule of immunization, blood sampling and
parasite challenge of Aotus lemurinus griseimembra.
Day (week) Immunization Blood sampling Challenge*
0 (1) X X
14 (2) X
28 (4) X X
46 (6) X
69 (10) X X
811 (12) X
97 (14) X X "
120 (17) X
The day of sampling and/or immunization is shown with the appropriate week
of each time point shown in brackets.
*i.v. injection (1 x 105 P. falciparum FVO parasites - ring stage).
1Parasite challenge Go/No Go decision point, based on IFA titer.
"Drug treatment criteria: Parasitemia $5% and/or haematocrit #20%.
doi:10.1371/journal.pone.0083704.t002
Figure 2. A. Antigen specific antibody titers of sera from Aotus monkeys immunized with the GST-FVO Block 2 fusion protein. Serum samples
collected at the time points listed in Table 2 were tested for reactivity with cleaved, purified FVO MSP-1 Block 2. Small arrows indicate immunization
time points. Large arrow indicates P. falciparum challenge time point. Titers were calculated by interpolation from titration curves for each serum
sample, with the endpoint titer defined as the dilution that gave an optical density value of 0.1. B. Parasite-reactive antibody titers of sera from four
immunized Aotus (A53, A66, A9801, A9802) plus control animals (A9804, A9902). Sera were tested by IFA against the Wellcome P. falciparum strain
(which has an identical MSP-1 Block 2 sequence to FVO). Hollow symbols, immunized animals; filled symbols, control (non-immunized) animals. Small
arrows indicate immunization time points.
doi:10.1371/journal.pone.0083704.g002
MSP-1 Block 2 Vaccine Protects Aotus Monkeys
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all known repetitive sequences from the MAD20 Block 2 serotype,
and peptides from the non-repetitive flanking regions of the
MAD20 Block 2 serotype. Analysis of day 97 sera from the four
animals showed a striking difference in epitope specificity between
the two protected monkeys that controlled infection (A53 and A66,
which had the highest IFA titers) and the two non-protected
animals (A9801 and A9802, which had four-fold lower IFA titers).
Sera from protected animals A53 and A66 both contained
antibodies specific for the repetitive amino acid sequences in the
central part of the FVO Block 2 sequence (Figures 4A and 4C and
Figure 5). The two non-protected animals had very low levels of
these antibodies, and a very narrow range of peptide specificity,
recognizing only one peptide weakly [SVASGGSVASGG]
(Figure 4B and 4D). Serum from all animals had detectable
antibodies to the non-repetitive flanking sequences of the FVO
Block 2 antigen, which were of similar intensity in all four samples
(Figure 4, all panels). This selective recognition of Block 2 peptide
epitopes has been observed in mice immunized with MSP-1 Block
2 antigens, especially when formulated with adjuvants less
powerful than Freund’s complete adjuvant [32,42]. Thus the
main difference between protected and non-protected animals
appears to be a broader epitope specificity of antibodies in the
protected animals, which is reflected in the higher IFA titers in the
two protected monkeys. The development of these responses for all
animals over the immunization period is shown as a heat map in
Figure 5. Antibodies to the flanking regions of FVO Block 2
appeared after the first immunization and remained high in all
four animals. By contrast, repeat sequence specific antibodies were
not detectable until after the second immunization in three
animals (day 46, Figure 5). In the two protected animals, A53 and
A66, these antibodies were maintained or enhanced in all
subsequent serum samples, whereas the two non-protected animals
either failed to maintain the weak reactivity initially detected
(A9802, Figure 5) or failed to produce any significant levels of
antibody to any repeat sequence epitope (A9801, Figure 5).
Parasite–specific antibodies in Aotus sera, pre- and post-
challenge
Serum samples from each monkey on day 97 (day 0 of
challenge) and day 120 (23 days post-challenge) were used to
detect parasite proteins from schizont extracts by Western blotting,
using proteins extracted from Wellcome (Block 2 homologous) and
3D7 (Block 2 non-homologous) parasites. In all four animals it was
possible to detect antibodies reacting with the N-terminal p83
fragment of mature Wellcome MSP-1, which contains the Block 2
region [6,43,44] (Figure 6, arrowed). The strongest pre-challenge
reactivity was seen in monkey A66, where a distinct band specific
for schizont MSP-1 from the Wellcome isolate (but not MSP-1
from 3D7 parasites) was clearly visible (Figure 6, A66 left side,
arrowed). All other reactivities in the day 97 samples, including the
strong reactivity with a ,50 kDa protein seen in all lanes, are
caused by reactivity of the secondary HRP-conjugated anti-human
IgG antibody used with human IgG present in the parasite extracts
(Figure 6, all panels, left side).
In three out of four animals, there is a distinct, strain-specific
boost in reactivity to the p83 component of MSP-1, except for
A9801, where reactivity with the MSP-1 p83 component is
undetectable in the day 120 sample, despite reactivity at day 97
(Figure 6, A9801, right side). A9801 was not protected after
challenge; the failure of the immunization to protect may therefore
be related to the lack of parasite-specific antibody boosting seen in
this animal. By contrast, animal A9802, which was also not
protected after challenge, showed a distinct, strain-specific boost in
reactivity against the homologous Wellcome p83 fragment of
MSP-1 23 days after challenge. This strain-specific but non-
protective response may reflect the 24-hour delay in the rise in
parasitemia seen in animal A9802 compared to the earlier rise in
parasitemia seen in animal A9801 (Figure 3).
Discussion
We have demonstrated in this study that Aotus monkeys can be
partially protected against a virulent, normally lethal challenge
with the FVO isolate of P. falciparum, by immunization with GST-
FVO MSP-1 Block 2 antigen. Importantly, protective titers of
antigen-specific antibody can be elicited using an adjuvant already
in use in humans, Montanide ISA51, which has been used in more
than 25 vaccine clinical trials with acceptable levels of reactoge-
nicity [45]. To our knowledge, very few malaria vaccine trials in
Aotus monkeys have successfully protected animals from blood
stage challenge using adjuvants acceptable for humans [46,47] and
most studies using such adjuvants have failed to provide any level
of protection using the highly virulent P. falciparum isolate FVO
challenge model [11,47,48]. A much larger number of trials have
been conducted using Complete Freund’s adjuvant, with varying
degrees of success in conferring protection in several Aotus models
[10,17,49–53]
More importantly, we have also shown that parasite-specific
antibody titers, as determined by IFA, correlate closely with
protective immunity to parasite challenge. Immunization of Aotus
monkeys with GST-FVO Block 2 induced antibodies to the
flanking sequences of the Block 2 antigen in all animals, but only
two animals also had antibodies to the internal repetitive epitopes
of Block 2 and were protected from parasite challenge. The
association between the presence of repeat-specific antibodies and
protection in this immunization and challenge trial is supported by
the observation that antibodies to repeat-specific epitopes within
MSP-1 Block 2 are associated with reduced risk of clinical malaria
episodes in cohorts of naturally exposed African children [25,30].
Evidence from this study indicates that the development of Block 2
repeat sequence-specific antibodies only occurs after repeated
immunization with the GST-FVO Block 2 antigen, as the two
protected animals only developed detectable antibodies to the
repeat sequences after two or three immunizations (Figure 5,
monkeys A53 and A66).
The reason that antibodies to the repetitive amino acid
sequences are almost undetectable in the immunized but non-
protected animals (A9801 and A9802) is unclear, but may reflect
the outbred nature of the monkeys used, or differences in ages of
Figure 3. P. falciparum parasitaemia development in all
challenged Aotus. Percentage parasitaemia is plotted against day of
sampling post challenge. Open symbols, immunized animals; filled
symbols, control (naı¨ve, non-immunized) animals.
doi:10.1371/journal.pone.0083704.g003
MSP-1 Block 2 Vaccine Protects Aotus Monkeys
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Figure 4. Recognition of peptide epitopes within MSP-1 Block 2. A panel of 38 N-terminally biotinylated dodecapeptides representing the
sequence diversity of the MSP-1 MAD20 Block 2 serotype was used in ELISA to map the antibody specificities present in the sera of immunized
monkeys, as described in Materials and Methods. Reactivity with individual peptides is shown in columns, with the strength of reactivity of each
serum sample with each peptide shown as ELISA optical density. The sequence of each peptide used is indicated on the X-axis below each column.
doi:10.1371/journal.pone.0083704.g004
Figure 5. A. Heat map of antibody reactivity to FVO Block 2 serotype peptides over the course of immunization. MSP-1 Block 2 specific peptide ELISA
is as described in Figure 4 and in Materials and Methods. Reactivities of sera from immunized Aotus are shown as blue rectangles for each peptide
tested, with darker colored bars indicating higher ELISA reactivity as shown in the figure key. Columns represent serum reactivity for each time point,
and each panel shows reactivity for all pre-challenge samples from each animal. B. Amino acid sequence of the FVO MSP-1 Block 2 antigen. MSP-1
Block 2 flanking sequences are shown in red and internal repeat sequences in blue, matching the peptide sequences shown in Panel A.
doi:10.1371/journal.pone.0083704.g005
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the animals (A9801 and A9802 were 4 years old, A53 and A66
were 7 and 6 years old), although all animals were adults (Table 1).
In naturally exposed humans, the need for the acquisition of
multiple antibody specificities to a network of antigen and epitope
specificities is thought to be one reason for the relatively slow
development of immunity to malaria [3,4]. It may be that the
intrinsic immunogenicity of disordered protein sequences is lower
than that of more conserved regions of MSP-1, such as the
flanking sequences of Block 2 [54] or conserved globular domains
such as MSP-119, which are more frequently encountered during
natural infections [23].
Promisingly, measurement of specific antibodies by IFA,
ELISA, Western blotting and peptide epitope mapping confirmed
that the responses to MSP-1 Block 2 induced by immunization
were boosted by challenge with P. falciparum (Figures 2 and 6). This
boosting of antibody responses by infection has significant
practical importance, as this confirms that the GST-FVO Block
2 antigen has sufficient immunological identity to the parasite
MSP-1 Block 2 region to stimulate appropriate and specific B cell
memory in the immunized animals.
In this trial, immunized animals were challenged with 16105
FVO ring stage parasites. Most recent studies using the highly
virulent P. falciparum strain FVO have challenged with parasite
numbers ranging from 16104 [11,13,47,55] to 56104 [10,56,57]
and occasionally 16105 [58]; thus we have used an inoculum at
the highest end of the range used in other studies. In addition,
Aotus lemurinus griseimembra monkeys are considered to be the most
susceptible species to infection with P. falciparum asexual blood
stages [59]. Montanide ISA51 has not been used as the sole
adjuvant in any other Aotus trial to our knowledge, having been
combined with Complete Freund’s adjuvant in all previously
published studies. Thus the combination of a 2-10 fold higher
parasite inoculum, the use of a human acceptable adjuvant such as
Montanide ISA51 and the highly susceptible species A. lemurinus
griseimembra indicates that this trial, although using only small
numbers of animals, has shown a highly significant protective
effect which is convincingly explained by very specific antibody
responses to defined epitopes within MSP-1 Block 2.
We conclude that immunization with a Block 2 antigen derived
from MSP-1 induces strongly protective immune responses, albeit
not in all immunized monkeys. Using close monitoring of the
antibody responses induced by vaccination, including fine-scale
epitope mapping of the response to immunization, we have further
validated the Block 2 region of MSP-1 as a promising malaria
vaccine candidate. Thus, our data are fully in line with the earlier
observations that protection from malaria in the field strongly
correlates with the presence of Block 2 antibodies [25,29,30,32].
The mechanism(s) by which antibodies to Block 2 act to inhibit
parasite growth and/or development in the host are not
understood, but like antibodies to other merozoite antigens (e.g.
MSP-2, MSP-3), they may have anti-parasite effects via Fc
receptor-mediated activation of innate immune cells, as measured
by assays such as antibody dependent cellular inhibition (ADCI)
[33] or antibody dependent respiratory burst [60]. Since MSP-1
Block 2 is highly polymorphic, in endemic settings acquiring a
repertoire of antibodies to repeat sequence variants from each
MSP-1 Block 2 type would require repeated infections with
parasite isolates presenting each of the three Block 2 serotypes. An
effective vaccine based on a polymorphic protein domain such as
MSP-1 Block 2 would therefore need to elicit antibodies to all
three MSP-1 Block 2 serotypes, including sequence and antigenic
variants within each type. This is an achievable requirement, as we
have now constructed and successfully pre-clinically tested such a
vaccine antigen [32].
The limited number of blood-stage vaccines that have reached
clinical trials have shown disappointing levels of efficacy, with only
three candidates reaching phase 2b studies [61]. Merozoite
antigens are often polymorphic, and the monomorphic merozoite
protein vaccines trialled thus far have shown, unsurprisingly,
allele-specific signatures of protection [62–64]. We identified this
polymorphic antigen region from MSP-1 that showed population-
level signatures of immune selection [29], and have been able to
produce an immunogenic vaccine antigen which can elicit
Figure 6. Reactivity of Aotus sera with parasite proteins.
Schizont extracts from the Wellcome (W) and 3D7 (3) isolates were
probed by Western blotting with sera from all four immunized animals.
Serum samples from day 97 (pre-challenge) and day 120 (post
challenge) from each animal were tested in parallel on contiguous
parts of the same membrane. Immunized animal code numbers are
shown on the left of each panel. Arrowheads indicate reactivity with the
N-terminal p83 proteolytic fragment of MSP-1. The dominant 50 kDa
band in all blots is the heavy chain of human IgG, recognized by the
secondary reagent (HRP conjugated anti-human IgG heavy chain).
doi:10.1371/journal.pone.0083704.g006
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antibodies to diverse allelic types of MSP-1 [32]. It is now possible
to develop a vaccine based on MSP-1 Block 2 that is designed to
protect against all parasite genotypes and resist immune escape.
Such a diversity covering blood stage vaccine, combined with an
effective pre-erythrocytic antigen would be an attractive option.
Materials and Methods
Animal welfare and ethical clearance
Aotus monkeys (Aotus lemurinus griseimembra) used in this study
were captive bred for research purposes. They were socially
housed at the BPRC facilities in cages of 1506756185 cm, under
compliance with the Dutch law on animal experiments, European
directive 86/609/EEC and with the ‘Standard for humane care
and use of Laboratory Animals by Foreign institutions’ identifi-
cation number A5539-01, provided by the Department of Health
and Human Services of the USA National Institutes of Health
(NIH). To minimize distress to the animals they were housed
under a reversed day/night rhythm so that animal handling
occurred when the animals were awake. Nonhuman primates were
used because no other models (in vitro or in vivo) were available for
testing of experimental human malaria vaccines. Standard feeding
regime consisted of Marex food for New World monkeys, water ad
libitum and food enrichment in the form of fruit chains (whole
fruit, apples, bananas and vegetables, peppers, endive etc, on a
chain). Cage enrichment was present in the form of ropes,
branches, elevated seating plateau and shelter cages. All animals
were daily monitored for health and discomfort. The local
independent ethical committee constituted conform Dutch law
(BPRC Dier Experimenten Commissie, DEC), approved all
research protocols prior to the start. The composition of the
DEC and the decision process are based on the Dutch
‘‘Experiments on Animals Act’’ (Wet op de Dierproeven) and
the ‘‘Experiments on Animals Studies Decision’’ (Dierproevenbe-
sluit). Both documents are available online on http://wetten.
overheid.nl. All experiments were performed according to Dutch
and European laws. The Council of the Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC
International) has awarded BPRC full accreditation. Thus, BPRC
is fully compliant with the international demands on animal
studies and welfare as set forth by the European Convention for
the Protection of Vertebrate Animals used for Experimental and
other Scientific Purposes, Council of Europe (ETS 123), Dutch
implementing legislation and the Guide for Care and Use of
Laboratory Animals. At the end of the experiment all monkeys
were radically cured with an oral dosage of mefloquine,
subsequently monitored for absence of blood stage parasites and
then returned to the colony. All intravenous injections and large
blood collections were performed under ketamine sedation, and all
efforts were made to minimize suffering.
MSP-1 FVO Block 2 construct
DNA was obtained from Aotus peripheral blood containing the
P. falciparum isolate FVO, which is used as the challenge strain for
Aotus monkeys at the Biomedical Primate Research center,
Rijswijk, the Netherlands. Parasite DNA was purified using the
method of Fenton et al. [65] and used as a template for an MSP-1
Block 2 specific PCR reaction. Each reaction contained 10 mM
Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.001% (w/v)
gelatin, 2 mM each dNTP, 2.5 units Taq DNA polymerase
(Roche Diagnostics Ltd., UK) and 1 mM each of the following
pairs of primers: forward primer (59 CTGGATCCAATGAAG-
GAACAAGTGGA 39) and reverse primer (59 GGGAATTCT-
TAACTTGAATTATCTGAAGG 39). Underlined portions of
each primer indicate non-MSP-1 sequences added to incorporate
BamHI and EcoRI restriction enzyme sites into the PCR products,
whereas non-underlined parts of these primers match specifically
the 59 and 39 ends of the MAD20 type Block 2 sequence of MSP-1.
A polymerase chain reaction (PCR) cycle of 95uC, 90 s; 50uC,
15 s; 72uC, 45 s was repeated for 35 cycles in each case.
Production of recombinant MSP-1 FVO Block 2 antigens
The PCR amplified Block 2 region of the FVO MSP-1 gene was
expressed in E. coli as a recombinant protein fused to the C-
terminus of glutathione S-transferase (GST) of Schistosoma japonicum
using the pGEX-2T vector [40]. This protein, known as GST-
FVO BL2, was produced and purified from cultures of E.coli
harboring the GST-FVO BL2 plasmid construct. The GST-FVO
BL2 fusion protein was purified to homogeneity by affinity
chromatography on a Hi-Trap GST column using the standard
manufacturer’s protocol (GE Healthcare, UK). Cleaved FVO
protein was produced by digestion of GST-FVOBL2 with
thrombin protease (Amersham) following the manufacturer’s
protocol. Thrombin and cleaved GST were removed from the
digested GST-FVO fusion protein by affinity chromatography of
the digested material on a Hi-Trap GST column, followed by
ultrafiltration (repeated five times) through a Vivaspin 20,000 Mr
cutoff centrifugal filter (Vivascience Inc., USA). The filtrate
contained the 5.3 kDa FVO Block 2 protein alone. Purified
proteins were dialyzed extensively against PBS, filter sterilized and
stored at 270uC until needed.
Immunogenicity testing
Purified GST fusion proteins were used as immunogens to
produce polyclonal antisera in inbred (CBA/Ca) and outbred
(MF1) strains of mice. Immunizing antigen was prepared by
diluting each purified protein in PBS (7.15 mM Na2HPO4,
2.85 mM KH2PO4, 3.58 mM KCl, 0.134 M NaCl), and formu-
lating in a series of five adjuvants: Alhydrogel (AlOH3) or
AdjuPhos (AlPO4) (Brenntag Biosector, Denmark); Montanide
ISA51 or Montanide ISA720 (Seppic, France) or non-ionic
surfactant vesicles (NISV) [66]. These mixtures were used to
immunize mice intraperitoneally. For each mouse, 50 mg of
protein in a final volume of 300 ml was used for each immunizing
dose. Three doses were given at monthly intervals and blood was
collected 12–14 days after the final dose. Sera from blood samples
were tested by IFA and ELISA for parasite- and antigen- specific
titers.
Indirect Immunofluorescence Assays (IFA)
Specificities and titers of mouse and Aotus antisera elicited by
immunization with the recombinant FVO Block 2 proteins were
compared by indirect immunofluorescence assays (IFA) on fixed
parasite preparations as described (2;6). Serial dilutions of the
antisera (1:50 – 1: 51,200), or control monoclonal antibodies, were
made in PBS containing 1% BSA and 0.01% sodium azide. A
25 ml volume of each antiserum was incubated on a well of a
multispot slide (Hendley, Essex, UK) with acetone-fixed schizonts
at room temperature for 30 min, followed by washing of the slides
in PBS (1 min/5 min/5 min). The slides were dried for 10 min at
50uC, then each spot was incubated with 15 ml of 1:80 dilution of
FITC (fluorescein isothiocyanate) conjugated rabbit anti-mouse Ig
(ICN) for 30 min at room temperature. After two washes in PBS,
the slides were immersed in a solution of 0.1% (w/v) Evans Blue
and 0.001% (w/v) DAPI (49,6-diamino-2- phenylindole, Sigma) in
PBS for 5 min to counter stain erythrocytes and parasite nuclei
respectively. The slides were washed and mounted in Citifluor
(City University, London) under cover-slips. The parasites were
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visualized by DAPI-fluorescence (DNA specific) and antibody-
reactive parasites by FITC-fluorescence (Ab specific) with incident
light of 450–490 nm and 390–440 nm respectively, at a magni-
fication of x 600.
Immunization and challenge protocol for Aotus monkeys
Eight adult Aotus lemurinus griseimembra monkeys were selected
from a group of eleven animals, on the basis of non-reactivity with
P. falciparum parasites, as measured by IFA at the Biomedical
Primate Research Centre (BPRC), Rijswijk, Netherlands and by
non-reactivity in an MSP-1 Block 2 ELISA in Edinburgh, using
serum from routine health checks. One animal was reserved as
parasite donor for the other seven, in the event of parasite
challenge proceeding. The other seven animals were assigned to
one group of four and one group of three monkeys, with age,
weight and sex matched. A summary of the animals used is given
in Table 1.
Four animals (A9801, A9802, A53, A66) were immunized with
100 mg of GST-FVO Block 2 formulated in Montanide ISA51,
prepared according to the manufacturer’s protocol (Seppic, Paris,
France). Three control animals (A9804, A55, A9902) were
immunized with PBS in Montanide ISA51. Animals were
immunized by i.m. injection three times with the same dose on
days 1, 28 and 69. Blood samples (1–3 ml) were taken from each
animal on days 1, 14, 28, 46, 69, 81, 97, and 120. Sera collected
from animals on days 1, 14, 28 and 46 were sent together to
Edinburgh for analysis by ELISA and IFA, to check for anti-Block
2 and anti-parasite antibody titers respectively. Samples were sent
‘‘blinded’’ to the Edinburgh investigators to prevent bias. In a
similar manner, sera collected on day 81 (and from day 69) were
sent to Edinburgh for IFA and ELISA analysis by day 84. The
schedule of immunization and sampling is summarized in Table 2.
Seroconversion of the immunized animals was confirmed on
day 84, as agreed in a prior immunization and challenge protocol
devised in advance of the study by the investigators and the
veterinarians at BPRC. We used the P. falciparum Vietnam Oak
Knoll (FVO) strain, which is adapted to growth in Aotus monkeys.
FVO intravenous infection has been shown to produce a
reproducible, lethal, high-density parasitemia in naive monkeys
with intact spleens [8,16,67]. A stock inoculum of FVO was
thawed on day 84 and injected into the donor animal (16105
parasites) on day 85. The animal was monitored for parasitaemia
by microscopy of Giemsa-stained blood smears from day 88
onwards, until a parasitaemia of 0.5-1% was reached. A blood
sample of 5 ml was taken and used to challenge all seven Aotus
monkeys by i.v. injection (16105 parasites in total volume of
0.5 ml). Injections were given to control animals first and last, and
all other animals were randomised in between these.
The general health of the animals was monitored daily and
noted in the study book. Parasitaemia in each animal was
monitored daily from day 97 onwards (blinded) by microscopic
examination of Giemsa-stained thin films prepared from a small
drop of blood from a needle prick in the monkey calf, from hand-
held monkeys. Monkeys were given a reward following this
procedure. If low parasitemia was observed for several days,
haematocrit was checked daily in addition to parasitaemia.
Animals were treated orally with 30 mg mefloquine in 3 ml
0.9% NaCl if parasitaemia reached $5% and/or haematocrit fell
to #25%. Treated monkeys were monitored several times by
microscopy of Giemsa-stained thin blood smears to verify
clearance of parasites. A final blood sample was taken from all
animals on day 23-post challenge.
Western blotting
Schizont proteins extracted in SDS-sample buffer (50 mM Tris
pH 6.8, 5% [v/v] 2-mercaptoethanol, 2% [w/v] SDS, 0.1% [w/
v] bromophenol blue, 10% [v/v] glycerol) were resolved by
discontinuous SDS-PAGE in 10% acrylamide gels and transferred
to Protran BA85 membranes (Schleicher and Schuell) in a
MiniProtean III electrophoresis unit (BioRad, UK) at a constant
current of 90 mA with cooling for 1 h. The membranes were
incubated in blocking buffer (5% non-fat milk powder in PBS,
supplemented with 0.05% Tween 20 and 0.02% NaN3) for 1 h,
and the transferred proteins then probed for 3 h with Aotus serum
samples from day 97 (parasite challenge day 0), and from day 120
(23 days post challenge) diluted 1:500 in blocking buffer. The
membranes were washed three times for 10 min each in washing
buffer (0.05% (v/v) Tween 20 in PBS), incubated with horseradish
peroxidase-conjugated rabbit anti-human IgG antibody (Dako,
UK) diluted 1:500 in washing buffer for 1 hour, washed three
times as above and finally rinsed in 10 mM Tris, 0.9% NaCl,
pH 7.4. Binding of mouse IgG to schizont proteins was visualised
using H2O2 and 4-chloro-1-naphthol as the chromogenic substrate
(5).
Enzyme-linked Immunosorbent Assay (ELISA)
Aotus sera were tested by ELISA for their ability to recognise the
recombinant MSP-1 fragments from Block 2. Wells of 96-well
plates (Immulon 4 HBX, Dynex) were coated with 50 ng/well of
recombinant antigens in 100 ml of coating buffer (15 mM
Na2CO3, 35 mM NaHCO3, pH 9.3) overnight at 4uC. The wells
were washed three times in washing buffer (0.05% Tween 20 in
PBS). Unoccupied protein binding sites were blocked with 200 ml/
well blocking buffer (1% [w/v] skimmed milk powder in washing
buffer) for 5 h at room temperature and washed again three times.
Mouse or Aotus sera diluted in the blocking buffer (100 ml per well)
were added to duplicate antigen-coated wells overnight at 4uC.
After three washes, the wells were incubated for 3 h with 100 ml
per well of horseradish peroxidase-conjugated polyclonal rabbit
anti-mouse IgG (at 1:1000) or rabbit anti-human IgG (at 1:5000)
(Dako Ltd., High Wycombe, UK) and washed three times before
incubating for up to 15 min at room temperature with 100 ml of
substrate (0.1 mgml21 o-phenylenediamine [Sigma] and 0.012%
H2O2) in development buffer (24.5 mM citric acid monohydrate
and 52 mM Na2HPO4, pH 5.0). The reaction was stopped with
20 ml of 2 M H2SO4 and absorbance was measured at 492 nm.
Endpoint titres were calculated by interpolation from titration
curves for each serum sample, with the endpoint titer defined as
the dilution that gave an optical density value of 0.1 at 492 nm.
Epitope mapping by biotinylated peptide ELISA
A set of 38 biotinylated dodecapeptides covering all possible
linear epitopes contained within MSP-1 MAD20 Block 2 type
sequences were synthesized by Mimotopes Pyt. Ltd. (Clayton,
Australia). ELISA plates (Immulon 4 HBX, Thermo Dynex) were
coated with 100 mL of 5 mg ml21 streptavidin (Sigma) and
incubated at 37uC until dry. Plates were stored in heat sealed
foil pouches with 1 g silica gel at room temperature until use.
Reactivity of sera against the peptide library was determined by
ELISA. Streptavidin-coated plates were washed in PBS-T (PBS/
0.05% Tween20) and blocked with blocking buffer (1% ByCoA,
Croda Healthcare, UK dissolved in PBS) for 5 hours at room
temperature. Peptide library plates were prepared by addition of
300 ng peptide per well, in duplicate, and plates were incubated
overnight at 4uC. Sera were added to each well (100 mL at 1:500
dilution) and incubated overnight at 4uC, then washed with PBS-
T. Dilutions of a species-specific HRP-linked secondary antibody
MSP-1 Block 2 Vaccine Protects Aotus Monkeys
PLOS ONE | www.plosone.org 9 January 2014 | Volume 9 | Issue 1 | e83704
(Dako, UK), appropriate to the serum being tested, were added to
each well and plates were incubated at room temperature for
3 hours. Plates were washed three times with PBS-T and OPD
substrate was added to each well. Reactions were stopped by
addition of sulfuric acid and absorbance was read at 492 nm using
a microplate absorbance reader (Multiskan Ascent, Thermo
Scientific, UK). Background reactivity was calculated as the mean
of all OD values in the lowest two quartiles (i.e. below median)+6
standard deviations. Peptide reactivity data was then categorized
into the following groups; high = background +1 OD, medium =
background +0.5 OD, low = greater than background, negative
= below background.
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